Healthcare Reform Brings Little Short-term Benefit For China’s Pharmaceutical Companies
This article was originally published in PharmAsia News
China's highly anticipated healthcare reform plan rollout (PharmAsia News, Apr. 8, 2009) has raised questions, especially about the details of essential drug pricing. The new plan modifies the previous price ceiling for retail drugs to the current government-recommended prices, providing more objectivity. For instance, the rural-to-city expense ratio now stands at 3:7, which may improve to 50:50 after the reform. However, some drug makers worry that essential drugs may be fixed at a much lower rate, eroding profits for quality products. Analysts believe the pharma industry will see little profit improvement in the next three years due to thorny drug-related issues such as essential drug catalog and dissociating hospital income and drug sales. (Click here for more - Chinese language)
You may also be interested in...
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.